On February 12, 2026, the FDA approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia. A boxed warning is the FDA's most serious safety label, and its presence on hormone therapies for over two decades shaped how millions of women and their doctors approached menopause treatment.
This is a significant shift. For the first time since the early 2000s, the federal agency responsible for drug safety is saying the evidence no longer supports those broad warnings.
Six Products, Four Categories of HRT
The FDA removed risk statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning labels on six specific hormone therapy products. These products span all four categories of menopausal HRT:
- Prometrium (progesterone capsules, 100 mg and 200 mg), a progestogen-alone therapy
- Divigel (estradiol gel), a topical systemic estrogen
- Cenestin (synthetic conjugated estrogens, A tablets), systemic estrogen
- Enjuvia (synthetic conjugated estrogens, B tablets), systemic estrogen
- Estring (estradiol vaginal system), topical vaginal estrogen
- Bijuva (estradiol and progesterone capsules), a combination therapy
These six are the first batch. An additional 29 pharmaceutical companies have submitted proposed labeling changes for future FDA review.
One warning remains in place: the endometrial cancer risk for systemic estrogen-alone products in women with a uterus. That distinction matters, and it reflects the FDA's approach of following the data rather than making a blanket change.
Two Decades of Warnings from One Study
The original boxed warnings trace back to the Women's Health Initiative (WHI), a major study that was halted early in 2002 after researchers identified a potential increase in breast cancer and cardiovascular risk among participants taking estrogen plus progestin. A second arm studying estrogen alone was stopped in 2004 over stroke concerns.
Those findings led the FDA to apply broad boxed warnings across hormone therapy products. Prescriptions dropped sharply. According to the FDA, about 41 million U.S. women were ages 45 to 64 in 2020, yet only about 2 million women ages 46 to 65 received a hormone therapy prescription.
The limitations of the WHI study have been widely discussed in the medical community since then. As the FDA noted in its November 2025 announcement initiating the warning removal, the average age of participants in the WHI was 63, over a decade past the average age of menopause onset, and the hormone formulation used is no longer in common use. Subsequent research has painted a different picture, particularly for women who start therapy earlier.
Randomized Studies Support Earlier Initiation
According to the FDA, randomized studies show that women who start hormone therapy within 10 years of menopause onset, generally before age 60, experience a reduction in all-cause mortality and fewer fractures. The agency cited these findings as part of a comprehensive scientific literature review, an expert panel held in July 2025, and a public comment period.
The Menopause Society, a leading medical organization in the field, has also weighed in. In a statement responding to the FDA's announcement, the organization supported removal of the boxed warning on low-dose vaginal estrogen and noted that risks are low for younger, healthy women initiating therapy closer to the menopause transition, while acknowledging that risks are greater for older women or those further from menopause onset.
FDA Commissioner Marty Makary framed the decision as a correction. He stated that the agency is delivering on its promise to provide women with "accurate, scientifically grounded information."
The Label Change Does Not Make Hormone Therapy Risk-Free
The removal of boxed warnings does not mean hormone therapy is without risk. All medications carry potential side effects, and HRT is no exception. The FDA's updated labeling still encourages women to consult the full prescribing information for detailed benefit and risk considerations.
Hormone therapy is also not appropriate for everyone. Women with certain medical histories may not be candidates, and the FDA continues to emphasize individualized risk-benefit conversations between patients and their healthcare providers.
Fewer Barriers to an Informed Conversation
For women who have been hesitant about hormone therapy because of safety concerns rooted in the old warnings, this FDA update may ease some of that hesitation. The science has moved forward, and the labeling now reflects that.
At RejuvinAge, we have seen firsthand how hormone therapy can improve quality of life for women dealing with hot flashes, sleep disruption, mood changes, low energy, and other symptoms of menopause. Many women arrive at our practice already aware that something feels off but unsure whether treatment is safe. This FDA decision gives both patients and providers a clearer foundation for those conversations.
If you have been on the fence about exploring hormone therapy, or if you tried it years ago and stopped because of the warnings, this may be a good time to revisit the conversation with a provider who specializes in hormone health.
Sources:
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, U.S. Food and Drug Administration, February 12, 2026.
HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy, U.S. Food and Drug Administration, November 10, 2025.
The Menopause Society Comments on the FDA Announcement on Hormone Therapy, The Menopause Society, November 14, 2025.
